USA Radiotherapy Market: By Type (External Beam Radiation Therapy (Linear Accelerators, Radionuclide Therapy, Particle Accelerator, Gamma Knife and Cyber Knife), Internal Radiation Therapy (Brachytherapy and IORT)), and Country Forecast to 2030

USA Radiotherapy Market installation base was approximately 5,466 in 2023 and grew at 4.4% CAGR during the forecast years (2024-2030) and was 4,519 installations in 2019. By 2030, it is anticipated that the USA radiotherapy market will have 7,395 installations. Radiation therapy, also known as radiotherapy, employs high doses of ionizing radiation to destroy cancer cells and inhibit their growth. Radiotherapy involves the utilization of high-energy particles or waves, such as X-rays, gamma rays, or electron beams, to deliver precise radiation doses to malignant tissues for the effective destruction of cancer cells while minimizing damage to the surrounding normal tissues.

For instance, the number of radiation therapy facilities in the U.S. increased from 1,987 in 2005 to 2,332 in 2020, reflecting a 17% growth. Approximately 70% of the U.S. population lives within 12.5 miles of a treatment facility.  Radiation therapy is segmented into different types which include External Beam Radiation Therapy (EBRT), Internal Radiation Therapy. External Beam Radiation Therapy (EBRT) held the highest market share during the forecast period. For instance, the external beam radiation therapy installation base was 3,708 in 2019 and has shown a compound annual growth rate growth of 5.0% over the past five years (2019–2023). Of the many device kinds, the linear accelerators had 3,273 installations in 2019, and 3,977 installations in 2023, and at a 4.6% compound annual growth rate. For about the last decade, the U.S. has become a ‘replacement market’ for linear accelerators (LINAC) with new machines on a 1:1 basis. The top 5 commonly used Linacs are: Siemens Linear Accelerators (Oncor/Primus/MD2), Varian 600C Linear Accelerators, Varian 2100C/D Linear Accelerators, Elekta SL Series and Precise Linear Accelerators, and Varian 21EX Linear Accelerators.

Internal radiation therapy held a significant market share over the period and is commonly used for cancers of the prostate, cervix, and breast, and may be employed alongside EBRT for enhanced treatment outcomes. For instance, the internal radiation therapy market had 811 installations in 2019 and has increased at a compound annual growth rate (CAGR) of 4.2% during the past five years (2019–2023). Furthermore, Radiotherapy services are more in demand when cancer treatment facilities and public awareness campaigns for cancer prevention and early diagnosis are launched.

For instance, the United States' spending on healthcare increased by 4.1% in 2022 to $4.5 trillion, or $13,493 per person. The percentage of the country's GDP that was spent on health was 17.3%. Additionally, the efficiency and efficacy of IORT primarily also drives the market. For instance, according to the article published in 2022, the effectiveness and safety of intraoperative radiotherapy (IORT) with low-energy X-rays (INTRABEAM®) for accelerated partial breast irradiation could effectively replace postoperative whole breast external beam radiotherapy for early breast cancer.

USA Radiotherapy Market Key Developments:

• In 2024, Eckert & Ziegler BEBIG GmbH, a subsidiary of Eckert & Ziegler SE dedicated to brachytherapy solutions for the therapy of prostate cancer and brain and eye tumors, received the MDR certificate for its proprietary prostate seeds from DEKRA Certification B.V. as one of the very first companies in this market.
• In October 2023, Elekta acquired the Xoft business from iCAD Inc. Elekta, the world leader in brachytherapy solutions, will now be able to offer electronic brachytherapy technology and provide an expanded range of cancer treatment options
• In 2019, Hitachi, Ltd. announced that the radiation therapy started at Nagamori Memorial Center of Innovative Cancer Therapy and Research at Kyoto Prefectural University of Medicine (“Nagamori Memorial Center of Innovative Cancer Therapy and Research “) which introduced Hitachi’s radiation therapy systems.